The renin-angiotensin-aldosterone system and its suppression

被引:325
作者
Ames, Marisa K. [1 ]
Atkins, Clarke E. [2 ]
Pitt, Bertram [3 ]
机构
[1] Colorado State Univ, Coll Vet Med, Dept Clin Sci, Ft Collins, CO 80523 USA
[2] North Carolina State Univ, Coll Vet Med, Dept Clin Sci, Raleigh, NC USA
[3] Univ Michigan, Sch Med, Dept Med, Ann Arbor, MI 48104 USA
关键词
angiotensin converting enzyme inhibitor; angiotensin receptor blocker; chronic kidney disease; heart failure; mineralocorticoid receptor blocker; proteinuric kidney disease; systemic hypertension; CONGESTIVE-HEART-FAILURE; LEFT-VENTRICULAR DYSFUNCTION; CONVERTING ENZYME-INHIBITION; VASCULAR SMOOTH-MUSCLE; MITRAL-VALVE DISEASE; INDUCED ANP SECRETION; II RECEPTOR BLOCKADE; MAINE-COON CATS; MINERALOCORTICOID RECEPTOR; BLOOD-PRESSURE;
D O I
10.1111/jvim.15454
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Chronic activation of the renin-angiotensin-aldosterone system (RAAS) promotes and perpetuates the syndromes of congestive heart failure, systemic hypertension, and chronic kidney disease. Excessive circulating and tissue angiotensin II (AngII) and aldosterone levels lead to a pro-fibrotic, -inflammatory, and -hypertrophic milieu that causes remodeling and dysfunction in cardiovascular and renal tissues. Understanding of the role of the RAAS in this abnormal pathologic remodeling has grown over the past few decades and numerous medical therapies aimed at suppressing the RAAS have been developed. Despite this, morbidity from these diseases remains high. Continued investigation into the complexities of the RAAS should help clinicians modulate (suppress or enhance) components of this system and improve quality of life and survival. This review focuses on updates in our understanding of the RAAS and the pathophysiology of AngII and aldosterone excess, reviewing what is known about its suppression in cardiovascular and renal diseases, especially in the cat and dog.
引用
收藏
页码:363 / 382
页数:20
相关论文
共 278 条
[21]   Efficacy of Spironolactone on Survival in Dogs with Naturally Occurring Mitral Regurgitation Caused by Myxomatous Mitral Valve Disease [J].
Bernay, F. ;
Bland, J. M. ;
Haggstrom, J. ;
Baduel, L. ;
Combes, B. ;
Lopez, A. ;
Kaltsatos, V. .
JOURNAL OF VETERINARY INTERNAL MEDICINE, 2010, 24 (02) :331-341
[22]  
BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945
[23]   Clinical evaluation of imidapril in congestive heart failure in dogs: results of the EFFIC study [J].
Besche, B. ;
Chetboul, V. ;
Lefay, M.-P. Lachaud ;
Grandemange, E. .
JOURNAL OF SMALL ANIMAL PRACTICE, 2007, 48 (05) :265-270
[24]   Regulation of aldosterone secretion: from physiology to disease [J].
Beuschlein, Felix .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2013, 168 (06) :R85-R93
[25]  
BIE P, 2000, AM J PHYSIOL-REG I, V278, pR
[26]   Macrophage Mineralocorticoid Receptor Signaling Plays a Key Role in Aldosterone-Independent Cardiac Fibrosis [J].
Bienvenu, Laura A. ;
Morgan, James ;
Rickard, Amanda J. ;
Tesch, Greg H. ;
Cranston, Greg A. ;
Fletcher, Elizabeth K. ;
Delbridge, Lea M. D. ;
Young, Morag J. .
ENDOCRINOLOGY, 2012, 153 (07) :3416-3425
[27]   CAPTOPRIL PROVIDES SUSTAINED HEMODYNAMIC BENEFITS IN DOGS WITH EXPERIMENTALLY INDUCED MITRAL REGURGITATION [J].
BLACKFORD, LW ;
GOLDEN, AL ;
BRIGHT, JM ;
BRIGHT, RM ;
GOMPF, RE .
VETERINARY SURGERY, 1990, 19 (03) :237-242
[28]  
Bolignano D, 2014, COCHRANE DB SYST REV, V4, P1
[29]   The incidence and implications of aldosterone breakthrough [J].
Bomback, Andrew S. ;
Klemmer, Philip J. .
NATURE CLINICAL PRACTICE NEPHROLOGY, 2007, 3 (09) :486-492
[30]   Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren plus valsartan) therapy [J].
Bomback, Andrew S. ;
Rekhtman, Yelena ;
Klemmer, Philip J. ;
Canetta, Pietro A. ;
Radhakrishnan, Jai ;
Appel, Gerald B. .
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2012, 6 (05) :338-345